Munro & Forster win PRCA Health and Wellbeing Award

pharmafile | November 28, 2011 | News story | Medical Communications COPD, ERS, Munro & Forster, PRCA 

Healthcare comms agency Munro & Forster has won an industry award for its innovative World Spirometry Day Campaign for the European Respiratory Society (ERS).

The campaign generated over 400 articles on the subject of lung testing, reaching an estimated 12% of the European population.

It is estimated that 23 Europeans die from a preventable lung disease every hour, the ERS and Munro & Forster used the inaugural World Spirometry Day to publicise the need for regular lung health tests using a spirometer, the most reliable measure available.

The award-winning campaign encouraged healthcare professionals across Europe to hold testing events for the public, and helped them to maximise attendance with a step-by-step media toolkit and pan-European news story urging the public to get a ‘lung MOT’.

Over 300 events and 100,000 spirometry tests took place and nearly 25% of those tested were referred on to their GP, potentially catching damaging conditions before it was too late. Media messages reached over one in ten of the European population at a cost of 50p per 1,000, and the campaign’s roving spirometer was the first story to get COPD talked about on ITV’s ‘This Morning’ in 20 years.

Munro & Forster MD, Julie Flexen commented: “We are delighted with this prestigious award win which yet again proves that creative and hard-working media relations coupled with on-the-ground PR can still generate considerable cut through and public action. We were very impressed with the other shortlisted entries so we were obviously over the moon with the win.”

Click here for more on the PRCA awards and other winners on the night.

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …


Verona Pharma submits FDA New Drug Application for COPD treatment

UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to …


European approval for AstraZeneca’s Trixeo Aerospace in moderate to severe COPD

The European Medicines Agency (EMA) has announced the approval of AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium …

Latest content